Nebivolol in chronic heart failure: Current evidence and future perspectives

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 6, 2010, Pages 983-992

  Lipsic, Erik ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

blocker; Chronic heart failure; Nebivolol; Nitric oxide; Sympathetic nervous system

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BISOPROLOL; CARVEDILOL; CELIPROLOL; CIMETIDINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOXETINE; METOPROLOL; NADOLOL; NEBIVOLOL; NITRIC OXIDE; PLACEBO; PROPRANOLOL; TIMOLOL;

ADD ON THERAPY; ADRENERGIC SYSTEM; BRADYCARDIA; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTION; HUMAN; HYPOTENSION; INSULIN SENSITIVITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OXIDATIVE STRESS; PARESTHESIA; REVIEW; SYSTOLIC HEART FAILURE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; BENZOPYRANS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; ETHANOLAMINES; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 77949882360     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003694650     Document Type: Review

References (70)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e121-181
2. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989
3. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 2006;113:799-805
4. Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008;101:1016-1022
5. Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4:361-371
6. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009;54:1747-1762
7. Bylund DB, Eikenberg DC, Hieble JP, et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46:121-136
8. Gauthier C, Leblais V, Kobzik L, et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998;102:1377-1384
9. Rozec B, Erfanian M, Laurent K, et al. Nebivolol, a vasodilating selective beta (1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 2009;53:1532-1538
10. El Armouche A, Zolk O, Rau T, Eschenhagen T. Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. Cardiovasc Res 2003;60:478-487
11. Engelhardt S, Bohm M, Erdmann E, Lohse MJ. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol 1996;27:146-154
12. de Jong RM, Willemsen AT, Slart RH, et al. Myocardial beta-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388. Eur J Nucl Med Mol Imaging 2005;32:443-447
13. Piacentino V III, Weber CR, Chen X, et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 2003;92:651-658
14. Colucci WS, Sawyer DB, Singh K, Communal C. Adrenergic overload and apoptosis in heart failure: implications for therapy. J Card Fail 2000;6(2 Suppl 1):1-7
15. Tuininga YS, van Veldhuisen DJ, Brouwer J, et al. Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment. Br Heart J 1994;72:509-513
16. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341-1362
17. Veverka A, Salinas JL. Nebivolol in the treatment of chronic heart failure. Vasc Health Risk Manag 2007;3:647-654
18. Van Nueten L, De Cree J. Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc Drugs Ther 1998;12:339-344
19. Brixius K, Bundkirchen A, Bolck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001;133:1330-1338
20. Agostoni P, Contini M, Cattadori G, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail 2007;9:827-833
21. Mutlu GM, Sznajder JI. Mechanisms of pulmonary edema clearance. Am J Physiol Lung Cell Mol Physiol 2005;289:L685-695
22. Moniotte S, Kobzik L, Feron O, et al. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 2001;103:1649-1655
23. Rozec B, Gauthier C. beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 2006;111:652-673
24. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl 2004;1:2-16
25. Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res 2009;32:1103-1108
26. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-684
27. Dessy C, Moniotte S, Ghisdal P, et al. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 2004;110:948-954
28. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005;112:1198-1205
29. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003;107:2747-2752
30. Jankowski M, Szczepanska-Konkel M, Kalinowski L, Angielski S. Cyclic GMP-dependent relaxation of isolated rat renal glomeruli induced by extracellular ATP. J Physiol 2001;530:123-130
31. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990;30:535-560
32. Cominacini L, Fratta PA, Garbin U, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003;42:1838-1844
33. Sule SS, Frishman W. Nebivolol: new therapy update. Cardiol Rev 2006;14:259-264
34. Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res 1998;38:419-431
35. de Boer RA, Voors AA, van Veldhuisen DJ. Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother 2007;8:1539-1550
36. Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther 2009;31:447-462
37. Grassi G, Trevano FQ, Facchini A, et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl 2003;2:35-40
38. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 1998;12:135-140
39. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006;24:591-596
40. Brune S, Schmidt T, Tebbe U, Kreuzer H. Hemodynamic effects of nebivolol at rest and on exertion in patients with heart failure. Angiology 1990;41:696-701
41. Brehm BR, Wolf SC, Gorner S, et al. Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur J Heart Fail 2002;4:757-763
42. Uhlir O, Dvorak I, Gregor P, et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J Card Fail 1997;3:271-276
43. Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005;7:631-639
44. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225
45. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure). J Am Coll Cardiol 2009;53:2150-2158
46. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259
47. Kamp O, Metra M, De Keulenaer GW, et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clin Res Cardiol 2010;99:75-82
48. Dobre D, van Veldhuisen DJ, Mordenti G, et al. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 2007;154:109-115
49. Triposkiadis F, Giamouzis G, Kelepeshis G, et al. Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure. Int J Clin Pharmacol Ther 2007;45:71-77
50. Patrianakos AP, Parthenakis FI, Mavrakis HE, et al. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study. Am Heart J 2005;150:985.e9-985.e18
51. Lombardo RM, Reina C, Abrignani MG, et al. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am J Cardiovasc Drugs 2006;6:259-263
52. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479
53. Food and Drug Administration. 11 January 2010, Meeting of the Cardiovascular and Renal Drugs Advisory Committee; 2010, Silver Spring, Maryland, USA. Available from: http://www.fda.gov/ downloads/AdvisoryCommittees/ CommitteesMeeting Materials/Drugs/Cardiovascularand RenalDrugsAdvisoryCommittee/ UCM199554.pdf
54. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351-357
55. de Groote P, Herpin D, Dievart F, et al. Treatment of heart failure with preserved systolic function. Arch Cardiovasc Dis 2008;101:361-372
56. Kindermann M, Reil JC, Pieske B, et al. Heart failure with normal left ventricular ejection fraction: what is the evidence? Trends Cardiovasc Med 2008;18:280-292
57. de Boer RA, Pinto YM, van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003;10:113-126
58. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2000;35:19-28
59. Nodari S, Metra M, Dei CL. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003;5:621-627
60. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 1994;89:2070-2078
61. van den Berg MP, van Gelder IC, van Veldhuisen DJ. Impact of atrial fibrillation on mortality in patients with chronic heart failure. Eur J Heart Fail 2002;4:571-575
62. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103:1428-1433
63. van Veldhuisen DJ, Aass H, El Allaf D, et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail 2006;8:539-546
64. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426-2435
65. Dobre D, van Veldhuisen DJ, Goulder MA, et al. Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. Cardiovasc Drugs Ther 2008;22:399-405
66. Sliwa K, Norton GR, Kone N, et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol 2004;44:1825-1830
67. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13
68. Muthumala A, Drenos F, Elliott PM, Humphries SE. Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail 2008;10:3-13
69. White HL, de Boer RA, Maqbool A, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003;5:463-468
70. Mason RP, Giles TD, Sowers JR. Evolving mechanisms of action of beta blockers: focus on nebivolol. J Cardiovasc Pharmacol 2009;54:123-128